

Philip N Patsalos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8349063/publications.pdf>

Version: 2024-02-01

76
papers

5,881
citations

136885

32
h-index

243529

44
g-index

121
all docs

121
docs citations

121
times ranked

3904
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiepileptic drugsâ€™ best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2008, 49, 1239-1276.	2.6	914
2	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , The, 2003, 2, 347-356.	4.9	447
3	The Importance of Drug Interactions in Epilepsy Therapy. <i>Epilepsia</i> , 2002, 43, 365-385.	2.6	412
4	Clinical Pharmacokinetics of Levetiracetam. <i>Clinical Pharmacokinetics</i> , 2004, 43, 707-724.	1.6	378
5	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. <i>Lancet Neurology</i> , The, 2003, 2, 473-481.	4.9	359
6	Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed. <i>Epilepsia</i> , 2000, 41, 1364-1374.	2.6	296
7	Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 347-363.	1.0	291
8	Drug interactions involving the new second- and third-generation antiepileptic drugs. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 119-140.	1.4	288
9	Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 526-548.	1.0	286
10	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. <i>Epilepsia</i> , 2015, 56, 12-27.	2.6	224
11	The New Generation of GABA Enhancers. <i>CNS Drugs</i> , 2001, 15, 339-350.	2.7	179
12	Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 4-29.	1.0	172
13	Drug Interactions with the Newer Antiepileptic Drugs (AEDs)â€™ Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs. <i>Clinical Pharmacokinetics</i> , 2013, 52, 927-966.	1.6	156
14	Investigation into the Role of N-Acetylaspartate in Cerebral Osmoregulation. <i>Journal of Neurochemistry</i> , 1995, 65, 275-281.	2.1	122
15	Properties of Antiepileptic Drugs in the Treatment of Idiopathic Generalized Epilepsies. <i>Epilepsia</i> , 2005, 46, 140-148.	2.6	106
16	Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. <i>Epilepsia</i> , 2017, 58, 1234-1243.	2.6	99
17	Drug Interactions with the Newer Antiepileptic Drugs (AEDs)â€™ Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1045-1061.	1.6	95
18	Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?. <i>Epilepsy and Behavior</i> , 2011, 20, 20-23.	0.9	91

#	ARTICLE	IF	CITATIONS
19	Antiepileptic Drugs. <i>Drug Safety</i> , 1993, 9, 156-184.	1.4	90
20	Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 227-238.	1.5	79
21	Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. <i>Epilepsy Research</i> , 2002, 48, 217-219.	0.8	64
22	Perampanel Serum Concentrations in Adults With Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 358-364.	1.0	58
23	Newer Antiepileptic Drugs. <i>Drug Safety</i> , 1994, 11, 37-67.	1.4	57
24	In Situ Metabolism of Levetiracetam in Blood of Patients with Epilepsy. <i>Epilepsia</i> , 2006, 47, 1818-1821.	2.6	53
25	Saliva and serum lacosamide concentrations in patients with epilepsy. <i>Epilepsia</i> , 2011, 52, 258-263.	2.6	50
26	Benzodiazepine-GABAA Receptors in Idiopathic Generalized Epilepsy Measured with [11C]Flumazenil and Positron Emission Tomography. <i>Epilepsia</i> , 1995, 36, 113-121.	2.6	47
27	Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. <i>Epilepsia</i> , 2020, 61, 1854-1868.	2.6	45
28	Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 699-715.	0.9	44
29	Lacosamide Serum Concentrations in Adult Patients With Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 494-498.	1.0	42
30	Volumetric Absorptive Microsampling: A New Sampling Tool for Therapeutic Drug Monitoring of Antiepileptic Drugs. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 681-692.	1.0	38
31	Effects of Discontinuation of Phenytoin, Carbamazepine, and Valproate on Concomitant Antiepileptic Medication. <i>Epilepsia</i> , 1991, 32, 101-115.	2.6	35
32	Relation Between Dosage of Carbamazepine and Concentration in Hair and Plasma Samples From a Compliant Inpatient Epileptic Population. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 15-20.	1.0	33
33	New Antiepileptic Drugs. <i>CNS Drugs</i> , 1994, 2, 40-77.	2.7	30
34	Methodologies used to identify and characterize interactions among antiepileptic drugs. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 281-292.	1.3	24
35	Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 48, 1-6.	0.9	23
36	Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 765-769.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Perampanel: What is its Place in the Management of Partial Onset Epilepsy?. <i>Neurology and Therapy</i> , 2013, 2, 13-24.	1.4	15
38	New developments in the treatment of partial-onset epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 455.	1.0	11
39	Pharmacokinetic characterization of favipiravir in patients with COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3516-3522.	1.1	11
40	Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 1215.	1.0	8
41	The new generation of anti-epileptic drugs. <i>Expert Opinion on Emerging Drugs</i> , 1999, 4, 87-106.	1.1	6
42	Predictability of metabolic antiepileptic drug interactions. , 2005, , 57-92.		6
43	Antiepileptic drug interactions in patients requiring psychiatric drug treatment. , 2005, , 350-368.		6
44	The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy. <i>Epilepsy Research</i> , 2018, 148, 17-22.	0.8	5
45	Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study. <i>BMC Neurology</i> , 2020, 20, 7.	0.8	5
46	Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force. <i>Epilepsia Open</i> , 2022, 7, 260-270.	1.3	5
47	Experimental studies of pharmacodynamic interactions. , 2005, , 208-227.		4
48	Interactions between antiepileptic drugs. , 2005, , 111-138.		3
49	Antiepileptic drug interactions in the elderly. , 2005, , 273-293.		3
50	Combination therapy with antiepileptic drugs: potential advantages and problems. , 2005, , 16-25.		3
51	Influence of food and drugs on the bioavailability of antiepileptic drugs. , 2005, , 93-110.		2
52	Pharmacodynamic principles and mechanisms of drug interactions. , 2005, , 181-192.		2
53	Methods for assessing pharmacodynamic interactions. , 2005, , 193-207.		2
54	Clinical studies of pharmacodynamic interactions. , 2005, , 228-240.		2

#	ARTICLE	IF	CITATIONS
55	Clinical studies of pharmacodynamic interactions between antiepileptic drugs and other drugs. , 2005, , 241-254.		2
56	Selection of drug combinations in clinical practice: current and future perspectives. , 2005, , 421-440.		2
57	Antiepileptic drugs in non-epileptic health conditions: possible interactions. , 2005, , 369-391.		1
58	Interactions between antiepileptic and non-antiepileptic drugs. , 2005, , 139-178.		1
59	Combination therapy of diseases: general concepts. , 2005, , 3-15.		1
60	Pharmacokinetic principles and mechanisms of drug interactions. , 2005, , 47-56.		1
61	Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy. , 2019, 50, .		1
62	Psychotropic Drugs. , 2022, , 319-335.		1
63	Antiepileptic drug interactions in children. , 2005, , 257-272.		0
64	Cognitive side-effects due to antiepileptic drug combinations and interactions. , 2005, , 403-418.		0
65	Pharmacogenetic aspects. , 2005, , 26-44.		0
66	Antiepileptic drug interactions in pregnancy. , 2005, , 294-324.		0
67	Antiepileptic drug interactions in handicapped and mentally retarded patients. , 2005, , 325-340.		0
68	Antiepileptic drugs and sex steroids. , 2005, , 341-349.		0
69	Drug monitoring in combination therapy. , 2005, , 392-402.		0
70	Future research: an experimental perspective. , 2005, , 441-457.		0
71	Future research: a clinical prospective. , 2005, , 458-474.		0
72	Psychotropic Drugs. , 2016, , 285-301.		0

#	ARTICLE	IF	CITATIONS
73	Clobazam. , 2016, , 23-27.		0
74	Perampanel. , 2022, , 227-227.		0
75	Stiripentol. , 2022, , 147-150.		0
76	Clobazam. , 2022, , 55-59.		0